| Literature DB >> 27995131 |
Anna Dvorkin-Gheva1, Gilles Vanderstocken2, Ali Önder Yildirim3, Corry-Anke Brandsma4, Ma'en Obeidat5, Yohan Bossé6, John A Hassell7, Martin R Stampfli8.
Abstract
Exposure of small animals to cigarette smoke is widely used as a model to study the pathogenesis of chronic obstructive pulmonary disease. However, protocols and exposure systems utilised vary substantially and it is unclear how these different systems compare. We analysed the gene expression profile of six publically available murine datasets from different cigarette smoke-exposure systems and related the gene signatures to three clinical cohorts. 234 genes significantly regulated by cigarette smoke in at least one model were used to construct a 55-gene network containing 17 clusters. Increasing numbers of differentially regulated clusters were associated with higher total particulate matter concentrations in the different datasets. Low total particulate matter-induced genes mainly related to xenobiotic/detoxification responses, while higher total particulate matter activated immune/inflammatory processes in addition to xenobiotic/detoxification responses. To translate these observations to the clinic, we analysed the regulation of the revealed network in three human cohorts. Similar to mice, we observed marked differences in the number of regulated clusters between the cohorts. These differences were not determined by pack-year. Although none of the experimental models exhibited a complete alignment with any of the human cohorts, some exposure systems showed higher resemblance. Thus, depending on the cohort, clinically observed changes in gene expression may be mirrored more closely by specific cigarette smoke exposure systems. This study emphasises the need for careful validation of animal models.Entities:
Year: 2016 PMID: 27995131 PMCID: PMC5165723 DOI: 10.1183/23120541.00029-2016
Source DB: PubMed Journal: ERJ Open Res ISSN: 2312-0541
Mouse datasets downloaded from Gene Expression Omnibus (GEO)
| 6 | A/J | Male | 8 | 3 RA/3 CS | 90 | 2R4F | |
| 6–7 | AKR/J | Male | 6–8 | 3 RA/3 CS | 90 | 2R4F | |
| 16 | C57BL/6 | Male | 12 | 4 RA/4 CS | 100–120 | 1R3F | |
| 16 | C57BL/6 | Female | 8–10 | 3 RA/3 CS | 500 | 3R4F | |
| 12 | C57BL/6 | Female | NA | 5 FA/5 CS | NA | NA | |
| 8 | BALB/C | Female | 6–8 | 5 RA/5 CS | >600 | 3R4F# | |
| 8 | CD-1 | Female | 13 | 4 RA/4 CS | 750 | 2R4F |
TPM: total particulate matter; RA: room air; FA: forced air; CS: cigarette smoke; NA: not applicable. #: filters removed.
FIGURE 1Combining datasets. a) Clustering of samples before the batch effect removal procedure (Distance-Weighted Discrimination; DWD) was performed. b) Clustering of samples after DWD. c) Clustering of samples after removing GSE8790 and samples from two control mice that clustered with the samples obtained from smoke-exposed mice. Samples were clustered using average linkage and Spearman correlation distance.
FIGURE 2Genes differentially expressed between the smoke-exposed mice in each model and the control group. Increasing fold changes are highlighted with the increasing level of shading. In each category the genes are sorted by the fold-change values obtained from GSE18344. The colour coding is different for the all fold changes and fold change ≥2.
FIGURE 3Functional interaction network based on the 234 differentially expressed genes. a) Functional network with annotated gene clusters. Each cluster is contained within a separate NTA: grey oval, with the ID superimposed on it. b) Expression of the gene clusters in each of the mouse models. Clusters containing at least one upregulated gene are marked in pink; clusters containing at least one downregulated gene are marked in green; clusters containing both up- and downregulated genes are marked in grey. Clusters not containing any differentially expressed genes are marked by black contour. Models are sorted based on the total particulate matter used in the model: from lowest (lower left corner) to highest (upper right corner).
Functional annotation of the gene clusters
| 6 | TLR signalling: unfolded protein response | DNAJB1, DNAJC5B, HSPA1A, HSPB1, SAA1, TLR2 | |
| 2 | TLR signalling | CD86, CXCL9 | |
| 6 | Chemokines: signalling | CCL17, CCL22, CCL4, CCR1, CXCL13, CXCL5 | |
| 3 | Chemokines: activity | CCL2, CCL3, CCL7 | |
| 2 | Chemokines: NOD-like receptor signalling | CXCL1, CXCL2 | |
| 5 | Muscle contraction | ACTN2, MYH6, MYL1, TCAP, TNNI3 | |
| 5 | Integrins | CD14, ITGAM, ITGAX, ITGB2, SPON2 | |
| 4 | Circadian clock | ARNTL, DBP, NR1D1, PER1 | |
| 3 | Osteoclast differentiation | CLEC5A, TREM2, TYROBP | |
| 3 | Interleukins: FC-epsilon receptor I signalling | FCER1G, FCGR2B, IL12B | |
| 2 | Interleukins | IL1R2, IL1RN | |
| 3 | p53 pathway | IGF1, IGFBP3, IGFBP6 | |
| 3 | – | AHRR, ARNT2, MAFB | |
| 2 | Class I MHC mediated antigen processing and presentation | CYBA, NCF4 | |
| 2 | Immune response (complement pathway) | C1QA, C1QB | |
| 2 | Glutathione metabolism | GCLC, GCLM | |
| 2 | Heterotrimeric G-protein signalling pathway-Gq alpha and Go alpha mediated pathway | RGS1, RGS16 |
There were no pathways or processes significantly represented by cluster 9. TLR: Toll-like receptor; NOD: nucleotide-binding oligomerisation domain; MHC: major histocompatibility complex.
FIGURE 4Clusters from the functional network. a) Models clustered by the numbers of differentially expressed genes in each of the clusters. Numbers of the differentially expressed genes are indicated on the heatmap. Branches of the vertical dendrogram are named using the cluster IDs (0–16). Each cluster is functionally annotated based on the Pathway Enrichment and Gene Ontology analyses (see table 3). Cluster 9 is marked by “–” since it did not show any significant representation of any of the known processes. #: cluster contained both up- and downregulated genes. b) Correlation between total particulate matter (TPM) and number of differentially regulated clusters across mouse models. *: indicates mouse models. TLR: Toll-like receptor; MHC: major histocompatibility complex; NOD: nucleotide-binding oligomerisation domain. r =0.9348, p-value = 0.0072.
Clinical characteristics of subjects
| 12 | 45 | 27 | 82 | 17 | 88 | |
| 5 (42%)/7 | 23 (51%)/22 | 6 (22%)/21 | 37 (45%)/45 | 8 (47%)/9 | 54 (61%)/34 | |
| 48.3±15.4 | 57.5±8.7 | 55.8±11.6 | 63±9.2 | 59.6±14.6 | 62±9.4 | |
| 0 | 37.9±17.4 | 0 | 53±21.8 | 0 | 53.7±27.1 | |
| 98.6±9.38 (7) | 73.3±19.8 (17) | 94.1±13.2 (4) | 75.1±14.4 (1) | 105.4±33.1 (7) | 76.4±18.2 (7) | |
| 98.8±7.3 (7) | 87.1±16.3 (18) | 96.5±12.5 (6) | 87. 1±13.5 (5) | 99.1±31.2 (6) | 86.7±15.7 (7) | |
Data are presented as mean±sd, unless otherwise stated. The number of missing values is shown in parentheses. LAVAL: Laval University; UBC: University of British Columbia; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity.
FIGURE 5Regulation of clusters in human datasets. a) Expression of the gene clusters in each human cohort. Clusters containing at least one upregulated gene are marked in pink; clusters containing at least one downregulated gene are marked in green; clusters containing both up- and downregulated genes are marked in grey. Clusters not containing any differentially expressed genes are marked by black contour. b) Models clustered by the numbers of differentially expressed genes in each of the clusters across human data and mouse models. Numbers of the differentially expressed genes are indicated on the heatmap. Branches of the vertical dendrogram are named using the cluster IDs (0–16). Each cluster is functionally annotated based on the Pathway Enrichment and Gene Ontology analyses (see table 3). Cluster 9 is marked by “–” since it did not show any significant representation of any of the known processes. #: cluster contained both up- and downregulated genes. c) Correlation between total particulate matter (TPM) and number of differentially regulated clusters across mouse models and human datasets. Human datasets are marked by horizontal lines indicating the number of regulated clusters in each dataset. *: indicates mouse models. Laval: Laval University; GRNG: Groningen; UBC: University of British Columbia; TLR: Toll-like receptor; MHC: major histocompatibility complex; NOD: nucleotide-binding oligomerisation domain.